BioVersys AG

Focus area/active in: Human Health, Therapeutics

Company/Organisation type: SME

About:
BioVersys AG is a privately owned clinical stage Swiss pharmaceutical company focusing on research and development of small molecules acting on novel bacterial targets with applications in antimicrobial resistance and targeted microbiome modulation. BioVersys addresses the high unmet medical need for new treatments against life-threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders. Our most advanced programmes address nosocomial infections of A. baumannii (BV100, Phase 1), and tuberculosis (BVL-GSK098, Phase 1) in collaboration with GSK and a consortium of the University of Lille.

Website: bioversys.com